ATNM News and Press, Actinium Pharmaceuticals Inc. From 05/07/24

Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern PR Newswire Dr. Farrukh Awan , Professor of Medicine, Division of Hematology Oncology at...

2024-05-02 14:31:50 ET More on Novartis, Novartis AG, etc. Novartis AG (NVS) Q1 2024 Earnings Call Transcript Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis AG 2024 Q1 - Results - Earnings Call Presentation Novartis to b...

2024-05-02 12:15:02 ET H.C. Wainwright analyst issues BUY recommendation for ATNM on May 2, 2024 11:08AM ET. The previous analyst recommendation was Buy. ATNM was trading at $8.46 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...

2024-04-29 12:53:15 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Actinium Pharmaceuticals (NYSEMKT: ATNM ) just reported results for the first quarter of 2024. Actinium Pharmaceuticals reported earnings per share of -31 cents. This was ...

Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting PR Newswire -- Iomab-B led bone marrow t...

2024-04-15 12:54:18 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks . Imagine you acquired shares of a popular, richly price...

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting PR Newswire -&...

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy PR Newswire Potential blockbuster opportunity for next-generation targeted radiotherapy conditioning with CAR T-cell therapy a m...

2024-03-24 08:01:00 ET Westport Fuel Systems ( WPRT ) is set to report its Q4 earnings on Monday after the closing bell. The stock, which has dropped about 24% over a 12-month period, has received a Buy rating from Wall Street analysts, while Seeking Alpha's Quant Rating system has ...

2024-03-19 12:31:34 ET More on Actinium Pharmaceuticals Actinium Pharmaceuticals: Closer To Realizing Its Potential (Rating Upgrade) Actinium shares surge on promising data for AML radiotherapy candidate Actinium, Fusion stocks rally on $4.1B RayzeBio takeover deal ...